Rosa Bertha Gutarra-Vilchez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rosa Bertha Gutarra-Vilchez has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Xavier Bonfill
Center for Research in Epidemiology, Economics and Oral Public Health (CIEESPO), Faculty of Dentistry, Universidad de La Frontera, Temuco 4811230, Chile
4 shared publications Demián Glujovsky
CEGYR (Centro de Estudios en Genética y Reproducción); Reproductive Medicine; Viamonte 1432, Buenos Aires Argentina
3 shared publicationsFacultad de Medicina Humana. Lima Universidad de San Martín de Porres
2 shared publicationsAlicia Aleman
Departamento de Medicina Preventiva y Social, Facultad de Medicina de la Universidad de la República de Uruguay, Montevideo, Uruguay
1 shared publicationAndrea Coscia
CEGYR (Centro de Estudios en Genética y Reproducción); Reproductive Medicine; Viamonte 1432, Buenos Aires Argentina
1 shared publication- Andrés Viteri-García
Universidad UTE, Quito, 170527, Ecuador
1 shared publication
Latest Publications
- Open Access
- 1 September 2026
- Published by Centro de Investigacion y Desarrollo Ecuador in Revista Vive
- Vol. 9 (27) , 1-19
Resultados clínicos comparativos de intervenciones en pacientes con infarto agudo de miocardio ST atendidos en un hospital público de Lima, Perú
Introducción: la cardiopatía isquémica representa el subgrupo más frecuente dentro de las enfermedades cardiovasculares y la mayor proporción de muertes atribuibles a este grupo. Objetivo: Contrastar los resultados clínicos de pacientes con infarto agudo de miocardio con elevación del segmento ST atendidos en un hospital público de Lima entre 2021 y 2026 ante la aplicación de estrategia farmacoinvasiva precoz o intervención coronaria percutánea. Materiales y Métodos: Se utilizó un enfoque cuantitativo, de tipo observacional, analítico, longitudinal y retrospectivo, con 348 pacientes seleccionados por muestreo no probabilístico por conveniencia. Resultados: El evento combinado principal ocurrió en 19.4 % del grupo farmacoinvasivo y 29.0 % del grupo intervención. No obstante, no existieron diferencias significativas en mortalidad, evento combinado principal ni eventos adversos mayores, y la supervivencia a 30 días fue similar entre grupos. Conclusión: Se encontró resultados clínicos favorables de la estrategia fármaco invasiva precoz frente al ICP, se sugiere estudios multicéntricos y prospectivos para evaluar el evento principal combinado.
- 1 September 2026
- Published by Centro de Investigacion y Desarrollo Ecuador in Revista Vive
- Vol. 9 (27) , 1-19
Open AccessResultados clínicos comparativos de intervenciones en pacientes con infarto agudo de miocardio ST atendidos en un hospital público de Lima, Perú
Introducción: la cardiopatía isquémica representa el subgrupo más frecuente dentro de las enfermedades cardiovasculares y la mayor proporción de muertes atribuibles a este grupo. Objetivo: Contrastar los resultados clínicos de pacientes con infarto agudo de miocardio con elevación del segmento ST atendidos en un hospital público de Lima entre 2021 y 2026 ante la aplicación de estrategia farmacoinvasiva precoz o intervención coronaria percutánea. Materiales y Métodos: Se utilizó un enfoque cuantitativo, de tipo observacional, analítico, longitudinal y retrospectivo, con 348 pacientes seleccionados por muestreo no probabilístico por conveniencia. Resultados: El evento combinado principal ocurrió en 19.4 % del grupo farmacoinvasivo y 29.0 % del grupo intervención. No obstante, no existieron diferencias significativas en mortalidad, evento combinado principal ni eventos adversos mayores, y la supervivencia a 30 días fue similar entre grupos. Conclusión: Se encontró resultados clínicos favorables de la estrategia fármaco invasiva precoz frente al ICP, se sugiere estudios multicéntricos y prospectivos para evaluar el evento principal combinado.
- Open Access
- 28 June 2025
- Published by Universidad de San Martin de Porres in Horizonte Médico (Lima)
- Vol. 25 (2) , e2435
Factores asociados a la adherencia del tratamiento de anemia en menores de cinco años del Centro de Salud San Pedro, Ayacucho, 2021
Objetivo: Determinar la adherencia al tratamiento de anemia y los factores asociados a su adherencia en menores de cinco años, del Centro de Salud San Pedro, Ayacucho, 2021. Materiales y métodos: Se realizó un estudio de enfoque cuantitativo, tipo analítico, observacional y de corte transversal. La población estuvo conformada por 138 madres de niños menores de cinco años diagnosticados con anemia. Los instrumentos utilizados fueron el cuestionario Factores asociados al tratamiento de anemia y el Cuestionario de Morisky-Green que mide la adherencia al tratamiento. Se calculó ji al cuadrado para buscar la asociación y se realizó una regresión logística multivariada. Se consideró significativo un p < 0,05 y un intervalo de confianza del 95 %. En todos los análisis se usó el SPSS versión 26. Resultados: Se observó que la adherencia al tratamiento de anemia fue del 26,8 % y los factores asociados fueron seis. Cinco de ellos incrementan la adherencia: enfermedad mayor de seis meses (3,9 veces más) (odds ratio ajustada [Ora]: 3,959, IC 95 %: 1,367-11,469), la edad materna menor de 35 años (11 % más) (ORa: 1,124, IC 95 %: 1,043-1,211), el tipo de familia nuclear (dos veces más) (ORa: 2,010, IC 95 %: 1,161-3,480), el grado de instrucción primaria (2,6 veces más) (ORa: 2,650, IC 95 %: 1,205-5,824), conocer que la anemia se cura con alimentación rica en hierro (3,1 veces más) (ORa: 3,153, IC 95 %: 1,144-8,685). Sin embargo, la edad menor de dos años del niño disminuye la adherencia en un 27 % (ORa: 0,732, IC 95 %: 0,546-0,981). Conclusiones: La adherencia al tratamiento de anemia en menores de cinco años fue baja y se identificaron seis factores asociados: cinco que aumentan la adherencia y uno que la reduce. Se recomienda intervenir sobre factores susceptibles de cambio como el grado de instrucción y los conocimientos relacionados con el tratamiento de la anemia.
- 28 June 2025
- Published by Universidad de San Martin de Porres in Horizonte Médico (Lima)
- Vol. 25 (2) , e2435
Open AccessFactores asociados a la adherencia del tratamiento de anemia en menores de cinco años del Centro de Salud San Pedro, Ayacucho, 2021
Objetivo: Determinar la adherencia al tratamiento de anemia y los factores asociados a su adherencia en menores de cinco años, del Centro de Salud San Pedro, Ayacucho, 2021. Materiales y métodos: Se realizó un estudio de enfoque cuantitativo, tipo analítico, observacional y de corte transversal. La población estuvo conformada por 138 madres de niños menores de cinco años diagnosticados con anemia. Los instrumentos utilizados fueron el cuestionario Factores asociados al tratamiento de anemia y el Cuestionario de Morisky-Green que mide la adherencia al tratamiento. Se calculó ji al cuadrado para buscar la asociación y se realizó una regresión logística multivariada. Se consideró significativo un p < 0,05 y un intervalo de confianza del 95 %. En todos los análisis se usó el SPSS versión 26. Resultados: Se observó que la adherencia al tratamiento de anemia fue del 26,8 % y los factores asociados fueron seis. Cinco de ellos incrementan la adherencia: enfermedad mayor de seis meses (3,9 veces más) (odds ratio ajustada [Ora]: 3,959, IC 95 %: 1,367-11,469), la edad materna menor de 35 años (11 % más) (ORa: 1,124, IC 95 %: 1,043-1,211), el tipo de familia nuclear (dos veces más) (ORa: 2,010, IC 95 %: 1,161-3,480), el grado de instrucción primaria (2,6 veces más) (ORa: 2,650, IC 95 %: 1,205-5,824), conocer que la anemia se cura con alimentación rica en hierro (3,1 veces más) (ORa: 3,153, IC 95 %: 1,144-8,685). Sin embargo, la edad menor de dos años del niño disminuye la adherencia en un 27 % (ORa: 0,732, IC 95 %: 0,546-0,981). Conclusiones: La adherencia al tratamiento de anemia en menores de cinco años fue baja y se identificaron seis factores asociados: cinco que aumentan la adherencia y uno que la reduce. Se recomienda intervenir sobre factores susceptibles de cambio como el grado de instrucción y los conocimientos relacionados con el tratamiento de la anemia.
- Open Access
- 27 September 2022
- Published by Universidad de San Martin de Porres in Horizonte Médico (Lima)
- Vol. 22 (3) , e1960
Calidad de atención y satisfacción de usuarias atendidas por teleconsulta en Ginecología Oncológica del Hospital Nacional Edgardo Rebagliati Martins de EsSalud, agosto a octubre del 2021
Objetivo: Determinar la relación entre la calidad de atención y la satisfacción de las usuarias atendidas por teleconsulta en Ginecología Oncológica de agosto a octubre del 2021. Materiales y métodos: Estudio observacional, transversal y prospectivo en 302 usuarias. Instrumentos: cuestionario SERVPERF modificado, para evaluar calidad; lista de cotejo según Minsa, para evaluar la estructura; ficha de registro de tiempos durante la teleconsulta, para evaluar el proceso. El análisis de datos se realizó con SPSS v.27 y con la f de Fisher con p < 0,05. Resultados: El cumplimiento del componente estructura fue de 66,67 % según el Minsa; para el proceso, el tiempo de espera para la teleconsulta fue de 1 a 7 días en 53,31 %, el tiempo de espera para la atención fue Conclusiones: Existe relación entre calidad de atención y satisfacción de las usuarias en teleconsulta. El componente proceso cumple con los requisitos establecidos y la estructura está en proceso. La calidad de atención es buena y la satisfacción es alta.
- 27 September 2022
- Published by Universidad de San Martin de Porres in Horizonte Médico (Lima)
- Vol. 22 (3) , e1960
Open AccessCalidad de atención y satisfacción de usuarias atendidas por teleconsulta en Ginecología Oncológica del Hospital Nacional Edgardo Rebagliati Martins de EsSalud, agosto a octubre del 2021
Objetivo: Determinar la relación entre la calidad de atención y la satisfacción de las usuarias atendidas por teleconsulta en Ginecología Oncológica de agosto a octubre del 2021. Materiales y métodos: Estudio observacional, transversal y prospectivo en 302 usuarias. Instrumentos: cuestionario SERVPERF modificado, para evaluar calidad; lista de cotejo según Minsa, para evaluar la estructura; ficha de registro de tiempos durante la teleconsulta, para evaluar el proceso. El análisis de datos se realizó con SPSS v.27 y con la f de Fisher con p < 0,05. Resultados: El cumplimiento del componente estructura fue de 66,67 % según el Minsa; para el proceso, el tiempo de espera para la teleconsulta fue de 1 a 7 días en 53,31 %, el tiempo de espera para la atención fue Conclusiones: Existe relación entre calidad de atención y satisfacción de las usuarias en teleconsulta. El componente proceso cumple con los requisitos establecidos y la estructura está en proceso. La calidad de atención es buena y la satisfacción es alta.
- Open Access
- 1 January 2021
- Published by Comprehensive Publications in International Journal of Clinical Obstetrics and Gynaecology
- Vol. 5 (1) , 306-312
Association between the pre-pregnancy body mass index and risk of cesarean section: A case-control study
Objective: To estimate the association between the pre-pregnancy Body Mass Index (BMI) and the weight categories with the risk of cesarean section in Peruvian women.Methods: A Case-control study was conducted. The present study included 13 734 pregnant women (cases=4578 and controls=9156). The pre-pregnancy BMI and overweight and obesity status were the main risk factors. Logistic regression was used to assess the association between the main exposures and cesarean section. Results: Higher BMI values were associated with cesarean delivery (adjusted Odds Ratio (aOR): 1.081, 95% CI 1.067-1.095, P<0.001). When bodyweight status was considered, women with overweight (aOR: 1.461, 95% IC 1.172-1.823, P: 0.001) and obesity (OR: 1.810, 95% IC 1.578-2.076, P<0.001) during the pre-pregnancy had a higher likelihood of cesarean section compared to those with normal weight.Conclusion: Pre-pregnancy higher BMI values, particularly those of overweight and obesity status were independent risks for cesarean delivery in Peruvian women.
- 1 January 2021
- Published by Comprehensive Publications in International Journal of Clinical Obstetrics and Gynaecology
- Vol. 5 (1) , 306-312
Open AccessAssociation between the pre-pregnancy body mass index and risk of cesarean section: A case-control study
Objective: To estimate the association between the pre-pregnancy Body Mass Index (BMI) and the weight categories with the risk of cesarean section in Peruvian women.Methods: A Case-control study was conducted. The present study included 13 734 pregnant women (cases=4578 and controls=9156). The pre-pregnancy BMI and overweight and obesity status were the main risk factors. Logistic regression was used to assess the association between the main exposures and cesarean section. Results: Higher BMI values were associated with cesarean delivery (adjusted Odds Ratio (aOR): 1.081, 95% CI 1.067-1.095, P<0.001). When bodyweight status was considered, women with overweight (aOR: 1.461, 95% IC 1.172-1.823, P: 0.001) and obesity (OR: 1.810, 95% IC 1.578-2.076, P<0.001) during the pre-pregnancy had a higher likelihood of cesarean section compared to those with normal weight.Conclusion: Pre-pregnancy higher BMI values, particularly those of overweight and obesity status were independent risks for cesarean delivery in Peruvian women.
- Open Access
- 30 December 2019
- Published by Universidad de San Martin de Porres in Horizonte Médico (Lima)
- Vol. 19 (4) , 6-13
Efecto de la intervención nasal y nasosinusal en calidad de sueño en el Hospital Edgardo Rebagliati Martins 2017
Objetivo: Determinar el efecto de la cirugía nasal y nasosinusal endoscópica sobre la calidad de sueño en el Servicio de Otorrinolaringología del Hospital Edgardo Rebagliati Martins durante el año 2017. Materiales y métodos: Estudio retrospectivo y longitudinal. La muestra es de 92 pacientes operados en quienes se evaluó la calidad de sueño mediante el Índice de calidad de sueño de Pittsburgh. Los datos fueron analizados con SPSS versión 24 y se realizó análisis univariado, Mann-Whitney, correlación de Spearman y prueba de rango con signo de Wilcoxon. Resultados: La calidad de sueño mejoró después de la operación nasal y nasosinusal endoscópica (pConclusiones: Las operaciones nasal y nasosinusal endoscópica tienen un efecto positivo sobre calidad de sueño en pacientes del Servicio de Otorrinolaringología del Hospital Edgardo Rebagliati Martins 2017.
- 30 December 2019
- Published by Universidad de San Martin de Porres in Horizonte Médico (Lima)
- Vol. 19 (4) , 6-13
Open AccessEfecto de la intervención nasal y nasosinusal en calidad de sueño en el Hospital Edgardo Rebagliati Martins 2017
Objetivo: Determinar el efecto de la cirugía nasal y nasosinusal endoscópica sobre la calidad de sueño en el Servicio de Otorrinolaringología del Hospital Edgardo Rebagliati Martins durante el año 2017. Materiales y métodos: Estudio retrospectivo y longitudinal. La muestra es de 92 pacientes operados en quienes se evaluó la calidad de sueño mediante el Índice de calidad de sueño de Pittsburgh. Los datos fueron analizados con SPSS versión 24 y se realizó análisis univariado, Mann-Whitney, correlación de Spearman y prueba de rango con signo de Wilcoxon. Resultados: La calidad de sueño mejoró después de la operación nasal y nasosinusal endoscópica (pConclusiones: Las operaciones nasal y nasosinusal endoscópica tienen un efecto positivo sobre calidad de sueño en pacientes del Servicio de Otorrinolaringología del Hospital Edgardo Rebagliati Martins 2017.
- 12 October 2018
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2018 (10) , CD010001
Vasodilators for women undergoing fertility treatment
Background The rate of successful pregnancies brought to term has barely increased since the first assisted reproductive technology (ART) technique became available. Vasodilators have been proposed to increase endometrial receptivity, thicken the endometrium, and favour uterine relaxation, all of which could improve uterine receptivity and enhance the chances for successful assisted pregnancy. Objectives To evaluate the effectiveness and safety of vasodilators in women undergoing fertility treatment. Search methods We searched the following electronic databases, trial registers, and websites: the Cochrane Gynaecology and Fertility Group (CGF) Specialised Register of controlled trials, the Cochrane Central Register of of Controlled Trials, via the Cochrane Register of Studies Online (CRSO), MEDLINE, Embase, PsycINFO, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Knowledge, the Open System for Information on Grey Literature in Europe (OpenSIGLE), the Latin American and Caribbean Health Science Information Database (LILACS), clinical trial registries, and the reference lists of relevant articles. We conducted the search in October 2017 and applied no language restrictions. Selection criteria Randomised controlled trials (RCTs) comparing vasodilators alone or in combination with other treatments versus placebo or no treatment or versus other agents in women undergoing fertility treatment. Data collection and analysis Four review authors independently selected studies, assessed risk of bias, extracted data, and calculated risk ratios (RRs). We combined study data using a fixed‐effect model and assessed evidence quality using Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE) methods. Our primary outcomes were live birth or ongoing pregnancy and vasodilator side effects. Secondary outcomes included clinical pregnancy, endometrial thickness, multiple pregnancy, miscarriage, and ectopic pregnancy. Main results We included 15 studies with a total of 1326 women. All included studies compared a vasodilator versus placebo or no treatment. We judged most of these studies as having unclear risk of bias. Overall, the quality of evidence was low to moderate for most outcomes. The main limitations were imprecision due to low numbers of events and participants and risk of bias due to unclear methods of randomisation. Vasodilators probably make little or no difference in rates of live birth compared with placebo or no treatment (RR 1.18, 95% confidence interval (CI) 0.83 to 1.69; three RCTs; N = 350; I² = 0%; moderate‐quality evidence) but probably increase overall rates of side effects including headache and tachycardia (RR 2.35, 95% CI 1.51 to 3.66; four RCTs; N = 418; I² = 0%; moderate‐quality evidence). Evidence suggests that if 236 per 1000 women achieve live birth with placebo or no treatment, then between 196 and 398 per 1000 will do so with the use of vasodilators. Compared with placebo or no treatment, vasodilators may slightly improve clinical pregnancy rates (RR 1.45, 95% CI 1.19 to 1.77; 11 RCTs; N = 1054; I² = 6%; low‐quality evidence). Vasodilators probably make little or no difference in rates of multiple gestation (RR 1.15, 95% CI 0.55 to 2.42; three RCTs; N = 370; I² = 0%; low‐quality evidence), miscarriage (RR 0.83, 95% CI 0.37 to 1.86; three RCTs; N = 350; I² = 0%; low‐quality evidence), or ectopic pregnancy (RR 1.48, 95% CI 0.25 to 8.69; two RCTs; N = 250; I² = 5%; low‐quality evidence). All studies found benefit for endometrial thickening, but reported effects varied (I² = 92%) and ranged from a mean difference of 0.80 higher (95% CI 0.18 to 1.42) to 3.57 higher (95% CI 3.01 to 4.13) with very low‐quality evidence, so we are uncertain how to interpret these results. Authors' conclusions Evidence was insufficient to show whether vasodilators increase the live birth rate in women undergoing fertility treatment. However, low‐quality evidence suggests that vasodilators may slightly increase clinical pregnancy rates. Moderate‐quality evidence shows that vasodilators increase overall side effects in comparison with placebo or no treatment. Adequately powered studies are needed so that each treatment can be evaluated more accurately.
- 12 October 2018
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2018 (10) , CD010001
Vasodilators for women undergoing fertility treatment
Background The rate of successful pregnancies brought to term has barely increased since the first assisted reproductive technology (ART) technique became available. Vasodilators have been proposed to increase endometrial receptivity, thicken the endometrium, and favour uterine relaxation, all of which could improve uterine receptivity and enhance the chances for successful assisted pregnancy. Objectives To evaluate the effectiveness and safety of vasodilators in women undergoing fertility treatment. Search methods We searched the following electronic databases, trial registers, and websites: the Cochrane Gynaecology and Fertility Group (CGF) Specialised Register of controlled trials, the Cochrane Central Register of of Controlled Trials, via the Cochrane Register of Studies Online (CRSO), MEDLINE, Embase, PsycINFO, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Knowledge, the Open System for Information on Grey Literature in Europe (OpenSIGLE), the Latin American and Caribbean Health Science Information Database (LILACS), clinical trial registries, and the reference lists of relevant articles. We conducted the search in October 2017 and applied no language restrictions. Selection criteria Randomised controlled trials (RCTs) comparing vasodilators alone or in combination with other treatments versus placebo or no treatment or versus other agents in women undergoing fertility treatment. Data collection and analysis Four review authors independently selected studies, assessed risk of bias, extracted data, and calculated risk ratios (RRs). We combined study data using a fixed‐effect model and assessed evidence quality using Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE) methods. Our primary outcomes were live birth or ongoing pregnancy and vasodilator side effects. Secondary outcomes included clinical pregnancy, endometrial thickness, multiple pregnancy, miscarriage, and ectopic pregnancy. Main results We included 15 studies with a total of 1326 women. All included studies compared a vasodilator versus placebo or no treatment. We judged most of these studies as having unclear risk of bias. Overall, the quality of evidence was low to moderate for most outcomes. The main limitations were imprecision due to low numbers of events and participants and risk of bias due to unclear methods of randomisation. Vasodilators probably make little or no difference in rates of live birth compared with placebo or no treatment (RR 1.18, 95% confidence interval (CI) 0.83 to 1.69; three RCTs; N = 350; I² = 0%; moderate‐quality evidence) but probably increase overall rates of side effects including headache and tachycardia (RR 2.35, 95% CI 1.51 to 3.66; four RCTs; N = 418; I² = 0%; moderate‐quality evidence). Evidence suggests that if 236 per 1000 women achieve live birth with placebo or no treatment, then between 196 and 398 per 1000 will do so with the use of vasodilators. Compared with placebo or no treatment, vasodilators may slightly improve clinical pregnancy rates (RR 1.45, 95% CI 1.19 to 1.77; 11 RCTs; N = 1054; I² = 6%; low‐quality evidence). Vasodilators probably make little or no difference in rates of multiple gestation (RR 1.15, 95% CI 0.55 to 2.42; three RCTs; N = 370; I² = 0%; low‐quality evidence), miscarriage (RR 0.83, 95% CI 0.37 to 1.86; three RCTs; N = 350; I² = 0%; low‐quality evidence), or ectopic pregnancy (RR 1.48, 95% CI 0.25 to 8.69; two RCTs; N = 250; I² = 5%; low‐quality evidence). All studies found benefit for endometrial thickening, but reported effects varied (I² = 92%) and ranged from a mean difference of 0.80 higher (95% CI 0.18 to 1.42) to 3.57 higher (95% CI 3.01 to 4.13) with very low‐quality evidence, so we are uncertain how to interpret these results. Authors' conclusions Evidence was insufficient to show whether vasodilators increase the live birth rate in women undergoing fertility treatment. However, low‐quality evidence suggests that vasodilators may slightly increase clinical pregnancy rates. Moderate‐quality evidence shows that vasodilators increase overall side effects in comparison with placebo or no treatment. Adequately powered studies are needed so that each treatment can be evaluated more accurately.
- 1 August 2016
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 203, 5-11
Identification and description of controlled clinical trials published in Spanish Gynaecology and Obstetrics journals and risk of bias assessment of trials on assisted reproductive techniques
- 1 August 2016
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 203, 5-11
Identification and description of controlled clinical trials published in Spanish Gynaecology and Obstetrics journals and risk of bias assessment of trials on assisted reproductive techniques
- 13 October 2014
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 10 (10) , CD010001
Vasodilators for women undergoing fertility treatment
Since 1978, when Patrick Steptoe and Robert Edwards achieved the birth of the first test tube baby, assisted reproductive techniques have been refined and improved. However, the rate of successful pregnancies brought to term has barely increased. Therefore closer evaluation of the interventions is needed along with working towards improving uterus receptivity. Vasodilators have been proposed to increase endometrial receptivity, thicken the endometrium and favour uterine relaxation, all of which could improve uterine receptivity and enhance the chances for successful assisted pregnancies. To evaluate the effectiveness and safety of vasodilators in women undergoing fertility treatment. We searched the following electronic databases, trial registers and websites: the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, the Menstrual Disorders and Subfertility Group (MDSG) Specialised Register of controlled trials, PsycINFO, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), The Cochrane Library, Web of Knowledge, the Open System for Information on Grey Literature in Europe (OpenSIGLE), the Latin American and Caribbean Health Science Information Database (LILACS) and ClinicalTrials.gov. The search was conducted in February 2014. No language restrictions were applied. Randomised controlled trials (RCTs) of vasodilators alone or in combination with other treatments compared with placebo or with other agents in women undergoing fertility treatment. Two review authors independently selected the studies, assessed the risk of bias and extracted data. Risk ratios (RRs) were calculated using the numbers of events in the control and intervention groups of each study. Study data were combined using a random-effects model, and evidence quality was assessed using Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE) methods. Ten studies with a total of 797 women were included in this review. Most of the studies were judged as having an unclear risk of bias. Three studies reported live births, two reported vasodilator-related side effects, 10 reported clinical pregnancies (diagnosed by differing criteria) and four reported other side effects (multiple gestation, miscarriage, ectopic pregnancy).Overall, no evidence suggested that treatment with vasodilators increased live birth rates compared with placebo or no treatment (RR 1.18, 95% confidence interval (CI) 0.82 to 1.69, P value 0.37, three RCTs, 350 women, I(2) = 0%, moderate-quality evidence). This indicates that among women undergoing fertility treatment who have a 24% chance of live birth without the use of vasodilators, between 19% and 40% will achieve live birth with the use of vasodilators.No evidence was found of a difference between vasodilators and placebo or no treatment in the incidence of treatment side effects (RR 1.63, 95% CI 0.33 to 7.93, P value 0.55, two RCTs, 258 women, I(2) = 32%, low-quality evidence). Nor did any evidence show a difference between them in terms of multiple gestation, spontaneous abortion/miscarriage or ectopic pregnancy rates. However few relevant data were available.Overall, treatment with vasodilators was associated with an increased clinical pregnancy rate compared with placebo or no treatment (RR 1.38, 95% CI 1.00 to 1.92, P value 0.05, eight RCTs, 717 women, I(2) = 0%, low-quality evidence). However, confidence intervals do not rule out no effect of the intervention, and when studies of vasodilators combined with another medication (vitamin E or oestrogen) were excluded, the effects of treatment with vasodilators alone on clinical pregnancy rates were more uncertain.The evidence was of low or moderate quality, and the main limitations were imprecision and lack of clarity about study methods. Risk of publication bias could not be assessed because of the low number of identified studies. Evidence was insufficient to show that vasodilators increased the live birth rate in women undergoing fertility treatment. However, low-quality evidence suggests that vasodilators may increase clinical pregnancy rates in comparison with placebo or no treatment. Evidence was insufficient to show whether any particular vasodilator, administered alone or in combination with other active medications, was superior, and evidence was insufficient to allow the review authors to reach any conclusions regarding adverse effects. Adequately powered studies are needed so that each treatment can be evaluated more accurately.
- 13 October 2014
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 10 (10) , CD010001
Vasodilators for women undergoing fertility treatment
Since 1978, when Patrick Steptoe and Robert Edwards achieved the birth of the first test tube baby, assisted reproductive techniques have been refined and improved. However, the rate of successful pregnancies brought to term has barely increased. Therefore closer evaluation of the interventions is needed along with working towards improving uterus receptivity. Vasodilators have been proposed to increase endometrial receptivity, thicken the endometrium and favour uterine relaxation, all of which could improve uterine receptivity and enhance the chances for successful assisted pregnancies. To evaluate the effectiveness and safety of vasodilators in women undergoing fertility treatment. We searched the following electronic databases, trial registers and websites: the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, the Menstrual Disorders and Subfertility Group (MDSG) Specialised Register of controlled trials, PsycINFO, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), The Cochrane Library, Web of Knowledge, the Open System for Information on Grey Literature in Europe (OpenSIGLE), the Latin American and Caribbean Health Science Information Database (LILACS) and ClinicalTrials.gov. The search was conducted in February 2014. No language restrictions were applied. Randomised controlled trials (RCTs) of vasodilators alone or in combination with other treatments compared with placebo or with other agents in women undergoing fertility treatment. Two review authors independently selected the studies, assessed the risk of bias and extracted data. Risk ratios (RRs) were calculated using the numbers of events in the control and intervention groups of each study. Study data were combined using a random-effects model, and evidence quality was assessed using Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE) methods. Ten studies with a total of 797 women were included in this review. Most of the studies were judged as having an unclear risk of bias. Three studies reported live births, two reported vasodilator-related side effects, 10 reported clinical pregnancies (diagnosed by differing criteria) and four reported other side effects (multiple gestation, miscarriage, ectopic pregnancy).Overall, no evidence suggested that treatment with vasodilators increased live birth rates compared with placebo or no treatment (RR 1.18, 95% confidence interval (CI) 0.82 to 1.69, P value 0.37, three RCTs, 350 women, I(2) = 0%, moderate-quality evidence). This indicates that among women undergoing fertility treatment who have a 24% chance of live birth without the use of vasodilators, between 19% and 40% will achieve live birth with the use of vasodilators.No evidence was found of a difference between vasodilators and placebo or no treatment in the incidence of treatment side effects (RR 1.63, 95% CI 0.33 to 7.93, P value 0.55, two RCTs, 258 women, I(2) = 32%, low-quality evidence). Nor did any evidence show a difference between them in terms of multiple gestation, spontaneous abortion/miscarriage or ectopic pregnancy rates. However few relevant data were available.Overall, treatment with vasodilators was associated with an increased clinical pregnancy rate compared with placebo or no treatment (RR 1.38, 95% CI 1.00 to 1.92, P value 0.05, eight RCTs, 717 women, I(2) = 0%, low-quality evidence). However, confidence intervals do not rule out no effect of the intervention, and when studies of vasodilators combined with another medication (vitamin E or oestrogen) were excluded, the effects of treatment with vasodilators alone on clinical pregnancy rates were more uncertain.The evidence was of low or moderate quality, and the main limitations were imprecision and lack of clarity about study methods. Risk of publication bias could not be assessed because of the low number of identified studies. Evidence was insufficient to show that vasodilators increased the live birth rate in women undergoing fertility treatment. However, low-quality evidence suggests that vasodilators may increase clinical pregnancy rates in comparison with placebo or no treatment. Evidence was insufficient to show whether any particular vasodilator, administered alone or in combination with other active medications, was superior, and evidence was insufficient to allow the review authors to reach any conclusions regarding adverse effects. Adequately powered studies are needed so that each treatment can be evaluated more accurately.
- 13 December 2013
- Published by Taylor & Francis in Human Fertility
- Vol. 17 (1) , 28-36
Systematic evaluation of the quality of clinical practice guidelines on the use of assisted reproductive techniques
Objective: To conduct a systematic evaluation of clinical practice guidelines (CPGs) on the use of assisted reproductive technologies. Methods: We searched Medline, the Turning Research into Practice database, and guidelines-specific databases from December 2006 to November 2011. Three reviewers independently assessed each Guideline using the Appraisal of Guidelines for Research Evaluation (AGREE) II instrument. A standardized score was calculated separately for each of the six domains. Results: Fourteen Guidelines were included. Overall, the quality of these was suboptimal. The scores for each AGREE II domain ranged between 37% and 80%. Three (22%) were deemed “Recommended”; nine (64%),“Recommended with modifications”; and two (14%), “Not recommended”. Agreement among reviewers was very good (Intraclass Correlation Coefficient: 0.915 [95% CI 0.807–0.970]). Conclusions: The overall quality of the CPGs on Assisted Reproduction Techniques published during the last 5 years is suboptimal. Most Guidelines present significant shortcomings in important domains such as “stakeholder involvement”, “rigor of development”, and “applicability”. Instruments such as the AGREE II and “the Grading of Recommendation Assessment Development and Evaluation” system could prove useful to improve CPGs in this field. Guideline users could benefit from the present results when choosing which guidelines to implement.
- 13 December 2013
- Published by Taylor & Francis in Human Fertility
- Vol. 17 (1) , 28-36
Systematic evaluation of the quality of clinical practice guidelines on the use of assisted reproductive techniques
Objective: To conduct a systematic evaluation of clinical practice guidelines (CPGs) on the use of assisted reproductive technologies. Methods: We searched Medline, the Turning Research into Practice database, and guidelines-specific databases from December 2006 to November 2011. Three reviewers independently assessed each Guideline using the Appraisal of Guidelines for Research Evaluation (AGREE) II instrument. A standardized score was calculated separately for each of the six domains. Results: Fourteen Guidelines were included. Overall, the quality of these was suboptimal. The scores for each AGREE II domain ranged between 37% and 80%. Three (22%) were deemed “Recommended”; nine (64%),“Recommended with modifications”; and two (14%), “Not recommended”. Agreement among reviewers was very good (Intraclass Correlation Coefficient: 0.915 [95% CI 0.807–0.970]). Conclusions: The overall quality of the CPGs on Assisted Reproduction Techniques published during the last 5 years is suboptimal. Most Guidelines present significant shortcomings in important domains such as “stakeholder involvement”, “rigor of development”, and “applicability”. Instruments such as the AGREE II and “the Grading of Recommendation Assessment Development and Evaluation” system could prove useful to improve CPGs in this field. Guideline users could benefit from the present results when choosing which guidelines to implement.
- 27 November 2013
- Published by Wiley in Prenatal Diagnosis
- Vol. 34 (4) , 327-334
Birth defects in medically assisted reproduction pregnancies in the city of Barcelona
- 27 November 2013
- Published by Wiley in Prenatal Diagnosis
- Vol. 34 (4) , 327-334
Birth defects in medically assisted reproduction pregnancies in the city of Barcelona